Cambridge Healthtech Institute’s Inaugural

Emerging Indications and Modalities

Progress in CNS and Rare Diseases, Gene and Cell Therapy, Fibrosis and Liver Diseases

June 2-4, 2020


Significant progress in the fields of genetics, protein science and drug discovery is driving a renewed interest in emerging indications outside of oncology, important indications such as CNS, rare diseases, fibrosis and liver disease. Moreover, new and exciting technologies such as cell, gene and gene-edited therapies are offering a new way of treating previously untreatable diseases, and are quickly advancing through the clinic.

CHI's Emerging Indications and Modalities conference provides a platform for pharma, biotech and academia to discuss and benchmark the latest advances in developing new drug targets and novel therapies across the fields of neuroscience, rare diseases, fibrosis and liver diseases, as well as the unique challenges facing cell and gene therapy development. How do your drug discovery and translational strategies compare?  

Coverage will include, but is not limited to:

 

CNS and Neuroscience

  • Underlying biology of CNS related disease biology
  • Review of recent developments and failures
  • Emerging CNS targets and validation strategies
  • Impacts of genetics
  • CNS translational strategies – models, biomarkers, imaging  

 

Rare Diseases, Gene and Cell Therapy

  • Enabling technologies for rare disease drug discovery
  • Emerging modalities for rare disease indications - gene therapy, CRISPR, RNAi
  • Preclinical development challenges for rare disease indications
  • Translational strategies for gene and gene-edited therapies

 

Fibrosis & Liver Diseases

  • Medical therapies on the horizon for fibrosis-prone organs: lung, liver, kidney, heart and skin
  • Cross-organ fibrosis molecular targets:integrins, TGFb and more
  • Fibrosis biomarkers and other translational challenges
  • Compounds in early-stage clinical trials for NASH (non-alcoholic steatohepatitis)
  • Promising therapies for HBV (hepatitis B virus)

 

If you would like to submit a proposal to give a presentation at this meeting, please click here.

 

The deadline for priority consideration is November 22, 2019.

 

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

 

For more details on the conference, please contact:
Daniel Barry

Senior Conference Director

Cambridge Healthtech Institute

Phone: 781-972-5452
Email: dbarry@healthtech.com

 

For partnering and sponsorship information, please contact:

Companies A-K
Rod Eymael
Manager, Business Development
Phone: 781-247-6286
Email: reymael@healthtech.com

 

Companies L-Z
Joseph Vacca, M.S.
Director, Business Development
Phone: 781-972-5431
Email: jvacca@healthtech.com